What is Brief History of Xeris Company?

How did Xeris redefine emergency glucagon treatment?

The stabilization of glucagon into a ready-to-use liquid transformed emergency hypoglycemia care, removing complex reconstitution steps and reducing user error during crises. Xeris used proprietary non-aqueous platforms to enable room-temperature stable injectables and simple delivery.

Founded in 2005 by Dr. Steven Prestrelski and John Prendergast, the company developed XeriSol and XeriJect platforms to stabilize proteins and scale into treatments for diabetes and endocrine disorders. By late 2025 it reached near cash-flow break-even with a diversified portfolio and over $200,000,000 in annual net product revenue.

What is Brief History of Xeris Company? It began as a chemistry-focused startup in Austin, moved headquarters to Chicago, and evolved into a commercial specialty pharma leveraging partnerships and platform technology. See Xeris Porter's Five Forces Analysis

Xeris Pharmaceuticals was incorporated in 2005 to solve aqueous drug stability limits by developing non-aqueous, room‑temperature stable liquid formulations; the founding team targeted the reconstitution burden of emergency injectables like glucagon. Founders Dr. Steven Prestrelski and John Prendergast leveraged protein formulation expertise and early SBIR and seed funding to commercialize the XeriSol platform.

Founding Story

Xeris Company history began in 2005 with a focus on non‑aqueous injectables, aiming to eliminate lyophilized reconstitution steps for emergency drugs such as glucagon.

• The founding of Xeris combined expertise in protein chemistry and formulation to address the reconstitution burden faced by clinicians and patients.
• Initial prototype: a stable liquid glucagon designed to remain intact at room temperature, later forming the basis of Gvoke.
• Early financing mixed SBIR grants, seed capital, angel investors, and later venture funding from firms including ARCH Venture Partners to fund clinical development.
• Technical validation showed multi‑year room‑temperature stability for peptide formulations, overcoming skepticism about non‑aqueous injectables.

Key milestones in the History of Xeris and Xeris Company timeline include incorporation in 2005, SBIR‑supported early R&D, prototype glucagon development, and venture financing enabling clinical trials; by 2025 the company had advanced Gvoke to market authorization and commercial launch efforts supported by partnerships and capital raises exceeding several hundred million dollars in cumulative funding rounds.

For more on strategic positioning and commercialization, see Marketing Strategy of Xeris

Complete Xeris Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Following lab-stage development, Xeris entered rapid institutional growth and clinical validation, relocating to Chicago and preparing for commercialization with a public offering and FDA approvals that broadened its therapeutic reach.

Public listing and capital raise

In June 2018 Xeris Pharmaceuticals completed an IPO on Nasdaq (XERS), raising approximately $86,000,000 to fund late-stage trials and commercial build-out for its lead glucagon product.

FDA approvals that launched commercialization

FDA approval in September 2019 of Gvoke PFS and the subsequent Gvoke HypoPen began the company’s commercial era, addressing acute needs for ready-to-use liquid glucagon in diabetes care.

Strategic acquisition and portfolio expansion

In October 2021 Xeris acquired Strongbridge Biopharma for $267,000,000, adding Keveyis and Recorlev and prompting formation of Xeris Biopharma Holdings, Inc. to support multi-therapeutic commercial operations.

Commercial scale-up and payer optimization

During 2022–2024 the company scaled its salesforce and improved payer coverage; by year-end 2024 Gvoke had captured a significant retail glucagon share and prescriptions trended upward while Recorlev gained traction in endocrinology.

Key milestones in the Xeris Company timeline include the move to Chicago to access life-sciences talent, the $86M IPO in 2018, FDA approvals for Gvoke in 2019, the $267M Strongbridge acquisition in 2021, and the structural transition to Xeris Biopharma Holdings to support diversified revenue streams and operational efficiency; see Revenue Streams & Business Model of Xeris for further context on the company’s evolving commercial model.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Milestones, Innovations and Challenges trace Xeris Company history through regulatory wins, platform breakthroughs and market headwinds that shaped its commercial and technical trajectory.

Xeris origins centered on the XeriJect platform, which enabled subcutaneous delivery of high-concentration biologics and reduced the need for intravenous infusions. Strategic collaborations with major pharma firms for high-value assets underscored the technology's commercial potential.

XeriJect subcutaneous delivery

Enabled high-concentration monoclonal antibody delivery that traditionally required long IV infusions, supporting faster administration and improved patient convenience.

Partnerships with major pharma

Collaborations with industry leaders focused on formulating blockbuster biologics, including work related to Teprotumumab, enhancing credibility and licensing opportunities.

Auto-injector expertise

Commercial know-how from Gvoke launches informed device design and messaging that emphasized reliability and ease-of-use versus competitor formats.

Regulatory accomplishments

FDA approval of Recorlev in 2021 marked a high-stakes regulatory win that materially altered the Xeris Company timeline and revenue prospects.

Patent estate

Maintains a patent portfolio extending into the 2030s, supporting long-term protection for delivery innovations and formulations.

Commercial agility

Lean innovation practices and focused investment choices improved resilience during market volatility and capital restructuring episodes.

Launching amid the pandemic exposed commercial vulnerabilities, including limited access to prescribers and intensified competition from Eli Lilly's Baqsimi nasal glucagon. Financial strain from heavy R&D spending and debt obligations required multiple capital restructurings and a pivot to profitability-focused operations.

Pandemic launch constraints

Gvoke sales were hampered by restricted physician office access and shifting patient behaviors; field teams adapted to virtual engagement and remote support.

Competitive pressures

Eli Lilly's Baqsimi intensified market competition, prompting a marketing pivot to highlight auto-injector reliability and pursue label expansions.

Financial restructuring

Debt to Hayfin Capital Management and sustained R&D costs led to capital restructurings and a disciplined 'path to profitability' initiated in late 2023.

Operational streamlining

Leadership optimized supply chains and prioritized high-return assets to conserve cash and align spending with commercialization milestones.

Investor confidence

Despite volatility, platform strength and regulatory achievements helped sustain investor support through rounds of restructuring.

Commercial focus

Concentrating on core assets and expanding indications aimed to improve revenue durability and reduce reliance on external financing.

For a strategic overview and additional context on growth decisions within Xeris Company history, see Growth Strategy of Xeris.

Xeris Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Timeline and Future Outlook: A concise chronology of Xeris Company history from founding in 2005 through milestones and a forward-looking view emphasizing the XeriJect platform and commercial growth.

Platformization as Core Strategy

Management is prioritizing the XeriJect platform to enable subcutaneous biologic delivery, targeting the growing injectable drug delivery systems market projected to exceed $120,000,000,000 by 2030.

Revenue and Growth Targets

Company guidance and analyst models target $300,000,000 in annual revenue by 2027, driven by Recorlev uptake and expanded Gvoke market share.

Partnership-led Pipeline Expansion

Ongoing collaborations with Merck and Regeneron, plus additional licensing deals, are expected to broaden XeriJect applications for large molecules and specialty injectables.

Commercial Foundation and Long-term Value

With a stable commercial base from Gvoke and Recorlev and break-even status in 2025, long-term upside depends on platform licensing and sustained product revenue growth; see the Target Market of Xeris for market context: Target Market of Xeris

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE